Fatty Liver Disease Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com

Share Article

RnRMarketResearch.com adds “Fatty Liver Disease – Pipeline Review, H1 2015” to its store. The report provides an overview of the Fatty Liver Disease’s therapeutic pipeline.

Fatty Liver Disease Therapeutics Pipeline Market Review H1 2015

Fatty Liver Disease Therapeutics Pipeline Market Review H1 2015

Past News Releases

RSS

The report “Fatty Liver Disease – Pipeline Review, H1 2015” provides comparative analysis on the therapeutic development for Fatty Liver Disease. Fatty liver disease is characterized by increased accumulation of fat, especially triglycerides, in the liver cells. Many people with fatty liver disease experience no symptoms, especially in the early stage of the disease. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/fatty-liver-disease-pipeline-review-h1-2015-market-report.html .

The report also reviews key players involved in the therapeutic development for Fatty Liver Disease and special features on late-stage and discontinued projects. Companies discussed in this Fatty Liver Disease – Pipeline Review, H1 2015 report include ACROVIS biostructures GmbH, ChemoCentryx, Inc., Conatus Pharmaceuticals Inc., Daewoong Pharmaceutical Co., Ltd., Dr. Falk Pharma GmbH, DURECT Corporation, Galmed International Ltd., Generon (Shanghai) Corporation Ltd., Genovate Biotechnology Co., LTD., Gilead Sciences, Inc., Huons Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Metabolic Solutions Development Company, LLC, Novartis AG
Protalix BioTherapeutics, Inc., Raptor Pharmaceuticals Corp., TCM Biotech International Corp, Tobira Therapeutics, Inc., Verva Pharmaceuticals Limited and Zafgen Inc.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are ACR-488, Aramchol, CCX-872, cenicriviroc mesylate, CSN-501, cysteamine DR, Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders, DV-928, DWP-10292, emricasan, etanercept biosimilar, F-652, HU-002, MAT-8800, MB-12066, methazolamide, MN-002, MSDC-0602, norursodeoxycholic acid, oltipraz, PCBB-7, pradigastat sodium, Px-102, Px-103, Px-104, Recombinant Protein for Atherosclerosis and Hepatic Steatosis, Small Molecule to Inhibit IKK and TBK1 for Cardiovascular, Gastrointestinal and Metabolic Disorders, Small Molecule to Inhibit Them1 for Metabolic, Immunology and Gastrointestinal Diseases, Small Molecules to Activate AMPK for Fatty Liver Disease, SR-9238, Synthetic Peptide for Cardiovascular, Gastrointestinal and Metabolic Disorders, TCM-606F, VVP-100-X and ZGN-839. Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=356478 . (This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases cover by this report include: Jan 12, 2015: Researchers uncover more clues to how drug reverses obesity, diabetes, fatty liver disease 114, Jul 22, 2014: Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 115, Apr 28, 2014: Galmed Pharmaceuticals Commences Patient Screening for Aramchol Pharmacokinetic and Food Effect Studies 116, Mar 03, 2014: Conatus Pharmaceuticals Extends Liver Disease Reach With Phase 2 NAFLD/NASH Trial 116, Dec 19, 2012: Scripps Florida Scientists Develop New Compound that Reverses Fatty Liver Disease 117, Oct 31, 2012: Phenex Pharma Completes Phase I Studies With FXR-Agonist Px-102 118, Oct 06, 2011: Metabolic Solutions Development Company Receives $1.1m NIH Grant To Further Investigate MSDC-0602 For Treatment Of Fatty Liver Disease 119, Oct 14, 2010: Galmed Initiates Phase II Clinical Trial Of Aramchol For Treatment Of Fatty Liver Disease 119 and Sep 21, 2008: Galmed Medical Research Initiates Its Phase I study Of Aramchol, Its Drug Candidate For Fatty Liver Disease 120.

List of Tables
Number of Products under Development for Fatty Liver Disease, H1 2015 11
Number of Products under Development for Fatty Liver Disease - Comparative Analysis, H1 2015 12
Number of Products under Development by Companies, H1 2015 14
Number of Products under Development by Companies, H1 2015 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2015 16
Comparative Analysis by Late Stage Development, H1 2015 17
Comparative Analysis by Clinical Stage Development, H1 2015 18
Comparative Analysis by Early Stage Development, H1 2015 19
Comparative Analysis by Unknown Stage Development, H1 2015 20
Products under Development by Companies, H1 2015 21
Products under Development by Companies, H1 2015 (Contd..1) 22
Products under Investigation by Universities/Institutes, H1 2015 23

List of Figures
Number of Products under Development for Fatty Liver Disease, H1 2015 11
Number of Products under Development for Fatty Liver Disease - Comparative Analysis, H1 2015 12
Number of Products under Development by Companies, H1 2015 13
Number of Products under Investigation by Universities/Institutes, H1 2015 16
Comparative Analysis by Clinical Stage Development, H1 2015 18
Comparative Analysis by Early Stage Products, H1 2015 19
Assessment by Monotherapy Products, H1 2015 44

Explore more reports on Therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics .

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
@RnRMR
since: 06/2012
Follow >
RnR Market Research
since: 08/2012
Like >
Follow us on
Visit website